CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, announced that it was awarded a contract from the U.S. Federal Government to advance development of its ActivShield™ technology. This innovative solution sterilizes medical devices and instruments without the need for a power source, making it a versatile solution for numerous environments, including rural areas, military settings and healthcare facilities with limited or no current sterilization capability..

伊利诺伊州水晶湖。--（商业新闻短讯）--药品和消费品剂量、配药和保护技术的全球领导者AptarGroup，Inc.（纽约证券交易所：ATR）宣布，它获得了美国联邦政府的合同，以推进其ActivShield™技术的开发。这种创新的解决方案无需电源即可对医疗设备和仪器进行消毒，使其成为多种环境的通用解决方案，包括农村地区，军事环境和医疗保健设施，目前的消毒能力有限或没有。。

ActivShield™ technology leverages Aptar CSP Technologies’ 20+ years of material science expertise and is built upon the company’s proven 3-Phase Activ-Polymer™ platform, a highly engineered active material science solution trusted by global brands to protect sensitive drug products, medical devices, drug delivery systems and probiotics..

ActivShield™技术利用了Aptar CSP Technologies 20多年的材料科学专业知识，并建立在该公司经验证的3相Activ Polymer™平台之上，该平台是一种高度工程化的活性材料科学解决方案，受到全球品牌的信赖，可保护敏感药物产品、医疗设备、药物输送系统和益生菌。。

ActivShield™ technology is a portable, novel sterilization modality that does not require conventional infrastructure, power, or extensive training, and more importantly, does not present the health risk associated with the use of Ethelyne Oxide (EtO). ActivShield™ uses a highly engineered Activ-Film™ material that emits a controlled amount of chlorine dioxide gas to sterilize a wide range of medical devices and instruments..

ActivShield™技术是一种便携式新型灭菌方式，不需要传统的基础设施，电源或广泛的培训，更重要的是，不存在与使用环氧乙烷（EtO）相关的健康风险。ActivShield™使用一种高度工程化的Activ Film™材料，该材料可释放受控量的二氧化氯气体，对多种医疗设备和仪器进行消毒。。

“As an innovation leader in pharma dosing, dispensing and protection technologies, we are proud to work with the U.S. Government to advance our ActivShield™ solution for the sterilization of medical devices and instruments in locations where a power source may not be available, further enhancing its versatility,” said Stephan B.

Stephan B.说：“作为制药剂量、配药和保护技术领域的创新领导者，我们很荣幸能与美国政府合作，推动我们的ActivShield™解决方案在可能无法使用电源的地区对医疗设备和仪器进行消毒，进一步增强其多功能性。”。

Tanda, Aptar President and CEO..

Aptar总裁兼首席执行官Mark。。

Aptar’s technology can be custom engineered to meet the needs of specific devices and conditions. Its stability throughout shelf life and compact size (Figure 1) makes it easy to stockpile, and all materials are manufactured in the United States.

Aptar的技术可以定制，以满足特定设备和条件的需要。它在整个保质期内的稳定性和紧凑的尺寸（图1）使其易于储存，所有材料均在美国制造。

ActivShield™ technology is well-positioned to fill unmet sterilization needs in remote or emergency response civilian settings, which could significantly reduce infection risks stemming from inadequately sterilized medical devices and instruments. Additionally, the technology could reduce reliance on expensive and unsafe sterilization techniques such as EtO, which has come under recent scrutiny by the EPA for toxic emissions..

ActivShield™技术能够很好地满足远程或应急响应民用环境中未满足的消毒需求，这可以显着降低消毒不充分的医疗设备和仪器引起的感染风险。此外，该技术可以减少对昂贵且不安全的灭菌技术（如EtO）的依赖，EtO最近已受到美国环保局（EPA）的有毒排放审查。。

For the military, ActivShield™ can help wounded service members, particularly those in far-forward environments, have access to sterilized instruments during critical pre-hospitalization periods, following severe injuries.

对于军方来说，ActivShield™可以帮助受伤的服务人员，特别是那些处于偏远环境中的人员，在严重受伤后的关键住院前期间可以使用消毒器械。

John Belfance, president of Aptar CSP Technologies, stated, “ActivShield™ technology is a breakthrough in material science technology that has the potential to dramatically expand reliable instrument sterilization for challenging environments, simplifying processes and helping to save lives. We are grateful for the government’s recognition, which supports the potential of this new technology, and look forward to bringing ActivShield™ technology to the forefront of sterilization techniques.”.

Aptar CSP Technologies总裁John Belfance表示：“ActivShield™技术是材料科学技术的一项突破，有可能极大地扩展可靠的仪器灭菌技术，以应对具有挑战性的环境，简化工艺并帮助挽救生命。我们感谢政府的认可，这支持了这项新技术的潜力，并期待着将ActivShield™技术推向灭菌技术的前沿。”。

The five-year contract is valued at approximately $4.8 million.

这份为期五年的合同价值约480万美元。

* This work is supported by the US Army Medical Research and Development Command under Contract No. HT9425-24-C-0078. The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation..

*这项工作得到了美国陆军医学研究与发展司令部的支持，合同号为HT9425-24-C-0078。本报告中包含的观点、意见和/或调查结果均为作者的观点、意见和/或调查结果，除非其他文件另有规定，否则不应将其解释为陆军立场、政策或决定的官方部门。。

About Aptar

关于Aptar

Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Aptar CSP Technologies leverages its active material science expertise to transform ideas into market opportunities, accelerate and de-risk the product development process, and provide complete solutions that improve consumers’ and patients’ lives.

Aptar是全球药品和消费品剂量、配药和保护技术的领导者。亚太地区服务于许多有吸引力的终端市场，包括制药、美容、食品、饮料、个人护理和家庭护理。Aptar CSP Technologies利用其活性材料科学专业知识将想法转化为市场机会，加速产品开发过程并降低风险，并提供改善消费者和患者生活的完整解决方案。

The company offers a complete set of services from concept ideation, to design and engineering, to product development, global production, quality control, and regulatory support that results in expedited speed-to-market. For more information, please visit www.csptechnologies.com and www.aptar.com..

该公司提供从概念构思、设计和工程设计到产品开发、全球生产、质量控制和监管支持的全套服务，加快了上市速度。有关更多信息，请访问www.csptechnologies.com和www.aptar.com。。

This press release contains forward-looking statements, including the potential outcomes and the value of the contract for the development of the ActivShield™ technology. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements.

本新闻稿包含前瞻性声明，包括ActivShield™技术开发合同的潜在成果和价值。前瞻性陈述通常可以通过与历史或当前事实不严格相关的事实来识别，并且可以使用诸如“期望”、“预期”、“相信”、“估计”、“未来”、“潜在”、“继续”和其他类似的表达或未来或条件动词，例如“将”、“应该”、“将”和“可能”来识别此类前瞻性陈述。

Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances.

前瞻性陈述是根据1933年《证券法》第27A节和1934年《证券交易法》第21E节的安全港规定做出的，并基于我们的信念以及我们所做的假设和目前可用的信息。因此，由于我们的运营和业务环境中存在已知或未知的风险和不确定性，我们的实际结果或其他事件可能与此类前瞻性陈述中明示或暗示的结果或其他事件存在重大差异，包括但不限于：收购的成功整合；监管环境；和竞争，包括技术进步。

For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Forms 10-Q.

有关这些以及其他风险和不确定性的更多信息，请参阅我们向美国证券交易委员会提交的文件，包括我们表格10-K和表格10-Q中“风险因素”和“管理层对财务状况和经营成果的讨论和分析”下的讨论。

We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law..

我们没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律另有要求。。